TRxADE HEALTH, Inc. (NASDAQ:MEDS) Short Interest Down 60.6% in July

TRxADE HEALTH, Inc. (NASDAQ:MEDS) was the target of a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 27,800 shares, a decline of 60.6% from the June 30th total of 70,600 shares. Based on an average trading volume of 121,600 shares, the days-to-cover ratio is presently 0.2 days. Approximately 5.4% of the shares of the company are short sold.

TRxADE HEALTH Trading Down 2.8 %

MEDS stock traded down $0.33 on Thursday, reaching $11.46. 22,234 shares of the company were exchanged, compared to its average volume of 249,578. TRxADE HEALTH has a 12 month low of $3.69 and a 12 month high of $44.56. The stock’s fifty day moving average price is $10.85 and its 200 day moving average price is $9.64.

TRxADE HEALTH (NASDAQ:MEDS) last announced its earnings results on Wednesday, June 26th. The company reported ($6.40) earnings per share (EPS) for the quarter. TRxADE HEALTH had a negative return on equity of 291.04% and a negative net margin of 177.96%.

TRxADE HEALTH Cuts Dividend

The firm also recently declared a dividend, which was paid on Wednesday, July 24th. Shareholders of record on Friday, July 19th were paid a dividend of $1.50 per share. The ex-dividend date was Friday, July 19th.

Institutional Investors Weigh In On TRxADE HEALTH

A hedge fund recently bought a new stake in TRxADE HEALTH stock. Virtu Financial LLC purchased a new position in shares of TRxADE HEALTH, Inc. (NASDAQ:MEDS) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,617 shares of the company’s stock, valued at approximately $109,000. Virtu Financial LLC owned approximately 0.75% of TRxADE HEALTH at the end of the most recent reporting period. 5.68% of the stock is owned by institutional investors.

About TRxADE HEALTH

TRxADE HEALTH, Inc operates as a health services information technology (IT) company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement; and designs, develops, owns, and operates a business-to-business web-based marketplace.